Manufacturer Can't Claim Exclusivity Over Trade Mark When It Is Derived From Principal Ingredient Of Drug: Delhi HC Dismisses Sun Pharma's Appeal
Live LawThe Delhi High Court recently rejected an appeal by Sun Pharma, claiming that Hetero Healthcare's drug used to treat advanced breast cancer had infringed its trademark. The appellant, Sun Pharmaceutical Laboratories Ltd., challenged an order by the Commercial Court dismissing its application under Order 39 Rules 1 & 2 of the Code of Civil Procedure, 1908 and filed a suit, alleging infringement of its trademark 'LETROZ' and passing off and seeking a decree of permanent injunction restraining the respondent from using the brand 'LETERO,' in respect of the pharmaceutical product in question. The Commercial Court has held that it is apparent that the mark adopted by SUN is nothing but the first six letters of the INN. It is apparent that both SUN and HETERO are using their marks, which are derived from the INN 'LETROZOLE', which is descriptive of the active ingredient of the drug, that is, 'LETROZOLE'" The High Court concurred with the view of the Commercial Court that prima facie, there is little possibility of confusion or deception in the drug's purchaser's mind.